Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Sleep Deprivation Taxes Neurons, Racks Up Brain Aβ?
25 September 2009. While the occasional all-nighter to cram for exams or finish a grant proposal may seem like no big deal, losing sleep night after night could take its toll on brain health in later life, two new studies suggest. Based on microdialysis experiments in live mice, Dave Holtzman, Washington University, St. Louis, Missouri, and colleagues report that extracellular amyloid-β levels in the brain fall during slumber and rise with wakefulness. They discovered that these Aβ dynamics rely on the hormone orexin, and that forcing animals to sleep or stay awake decreases or increases Aβ plaque formation accordingly in a mouse model for Alzheimer disease. Holtzman presented some of these findings last year at the Human Amyloid Imaging meeting in Chicago (see ARF conference story). The full report was published online yesterday in Science.

Earlier work from the Holtzman lab had shown that synaptic activity triggers Aβ release (Cirrito et al., 2005 and ARF related news story), suggesting that the sleep-deprived mice in the current study churned out more Aβ because their brains were revved up longer than usual. While this is hard to prove formally, a rat electrophysiology study published in yesterday’s issue of Neuron seems to lend support for that idea. Led by Giulio Tononi at the University of Wisconsin-Madison, researchers report that neuronal firing in the brain is lower during sleep, and that the firing drops or escalates further the longer an animal has been asleep or awake. “This may tie in very much to why we see Aβ levels higher during wake and lower during sleep, and help explain why sleep deprivation is harmful not only for neuronal function but also may lead to an increase in Aβ levels and amyloid accumulation over time,” Holtzman noted in an e-mail to ARF.

Holtzman and colleagues did not start thinking about sleep from the get-go. They were trying to get a handle on Aβ pathogenesis by studying how the peptide gets metabolized in the brain. Lead author Jae-Eun Kang and coworkers had shown that stress drives up extracellular Aβ levels (Kang et al., 2007 and ARF related news story), but wondered what happens under normal conditions. Using microdialysis techniques to measure brain interstitial fluid (ISF) Aβ in Tg2576 mice, the researchers were at first puzzled to see peptide levels going up or down at various times. Upon closer observation, they discovered a pattern: over a 24-hour period, mean Aβ levels were about 25 percent lower during the day than at night. With help from sleep experts at Stanford University, Palo Alto, California, the team rigged mice with electroencephalogram (EEG) electrodes to record waking and sleeping. They found that “it wasn’t light and dark but rather how long the animals had been awake that seemed to correlate best with levels of Aβ peptide,” Holtzman told ARF. The longer the animal had been awake, the higher the ISF Aβ levels, and vice versa for amount of time spent sleeping. This pattern held in wild-type mice and in young male volunteers whose cerebrospinal fluid Aβ levels were measured by lumbar catheters (see also Bateman et al., 2007). As such, the daily Aβ changes appeared to reflect normal physiology.

The researchers then determined the effect on ISF Aβ of forcing mice to stay up past their bedtime—a regimen perhaps equally grueling to the researcher who had to stand by for six hours using a paintbrush to rouse animals on the verge of dozing. “This was no trivial study. It took three years,” Holtzman said. The tedious monitoring paid off, however, with data showing higher ISF Aβ levels during sleep deprivation (compared to peptide levels 24 hours prior) and an immediate drop in Aβ once the animals were finally allowed to sleep.

Reasoning that higher levels of ISF Aβ tend to make the peptide more likely to aggregate over time, the researchers subjected AD transgenic mice (APPswe/PS1dE9) to chronic sleep deprivation to see the effect on brain Aβ deposition. They used mice that had not yet developed amyloid pathology, and kept them awake 20 hours daily for 21 days by placing them on a special platform that sends snoozers into a pool of water. As predicted, sleep-restricted animals had greater plaque deposition in multiple cortical regions, compared to animals that slept at will. Extrapolating to humans, the data “suggest that midlife sleep abnormalities may predispose you to a neurodegenerative disease,” Holtzman told ARF.

Furthermore, the researchers determined that the daily Aβ fluctuations are regulated by orexin, a hormone that stimulates wakefulness. When the researchers gave mice six-hour brain infusions of orexin at a time they would normally be asleep, ISF Aβ was elevated relative to peptide levels measured during the same period 24 hours prior. Conversely, mice treated with a compound that blocks orexin signaling slept more and had lower Aβ levels. These findings suggest the orexin pathway as a potential target for AD prevention, Holtzman said. Sleep disturbances are common in several neurodegenerative diseases (see Gagnon et al., 2008, for review), and research suggests that improving sleep and circadian rhythm in dementia patients may also improve their cognition (Ancoli-Israel et al., 2008; Riemersma-van der Lek et al., 2008 and ARF related news story).

Greek mythology offers different versions of what happened during the famous sleeping episode of King Minos's daughter, the goddess Ariadne, on the island of Naxos, which artists immortalized on vases, paintings, and this Roman sculpture. Most versions have to do with rivalry between Theseus and Dionysus. But forget the guys. Maybe Ariadne was simply giving her synapses a well-deserved rest from the tiring love triangle, the better to keep her brain Aβ levels down? Image credit: Creative Commons

Those findings seem to jibe with recent work by University of Wisconsin-Madison researchers, including Tononi, who propose that sleep is needed to refresh synapses overworked from the day’s activity (Gilestro et al., 2009 and ARF related news story). In that study, the scientists tracked synaptic markers in flies, finding that these proteins rise with sleep deprivation and fall during slumber. One drawback with flies, though, is that “you cannot measure the EEG. You cannot record brain waves. And although you can record neurons, it’s much more difficult,” Vladyslav Vyazovskiy, University of Wisconsin-Madison, told ARF. “Studying mammals gives the opportunity to get many more physiological measures.”

For the Neuron paper, first author Vyazovskiy and colleagues used rats, implanting their brains with electrodes thin enough to record just a few neurons at a time. They measured several parameters of neuronal firing, including frequency, synchrony, and the relationship between firing patterns and various sleep phases. Whereas other studies had compared neuronal activity in sleep and wake states, the researchers suspected that activity levels may differ not only depending on sleep-wake state but also on how long the animal had been awake or asleep. For example, “in the morning, you wake up and you are fresh and well-rested,” Vyazovskiy said. “In the evening, you are also awake, but you are tired and sleepy.”

Vyazovskiy and colleagues found that neurons fired at progressively higher frequencies the longer the rats stayed awake, and that firing rates dropped correspondingly the longer the animals were asleep. Given that neuronal activity is “very costly in terms of energy,” Vyzovskiy said, one tenet of the so-called synaptic homeostasis hypothesis is that sleep serves to downscale synapses—to control the metabolic costs of neuronal function. “We provide new support for this hypothesis by looking at the behavior of single neurons,” he told ARF.—Esther Landhuis.

References:
Kang J-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DH. Amyloid-beta Dynamics are Regulated by Orexin and the Sleep-Wake Cycle. Science 2009 Sept 24. Abstract

Vyazovskiy VV, Olcese U, Lazimy YM, Faraguna U, Esser SK, Williams JC, Cirelli C, Tononi G. Cortical Firing and Sleep Homeostasis. Neuron 2009 Sept 24;(63):865-878. Abstract

 
Comments on News and Primary Papers
  Comment by:  Eric Blalock
Submitted 16 October 2009  |  Permalink Posted 16 October 2009
  I recommend the Primary Papers

The recent report by Kang et al. suggests not only that amyloid may serve an important role in sleep regulation, but also further highlights the need for additional studies on its physiological role. The study shows that amyloid is at least a biomarker of sleep, but it is interesting to note that it may also provide a mechanistic link mediating orexinergic signaling that pushes brain systems toward sleep. These findings are especially compelling considering other identified physiological effects of amyloid/APP, for example, Aβ feedback synaptic inhibition (Hsieh et al., 2006) or amyloid-enhanced potassium channel conductance (Furukawa et al., 1996). These physiological effects may be linked to slow wave sleep oscillations and neuronal quiescence (Vyazovskiy et al., 2009).

However, it is also important to note that there are likely to be multiple players in sleep regulation. For example, earlier work indicates BDNF and Homer1a also play...  Read more


  Primary Papers: Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.

Comment by:  Martin Ingelsson
Submitted 30 December 2009  |  Permalink Posted 30 December 2009

In this work from Dave Holtzman’s lab, the influence of the sleep-wake cycle on Aβ metabolism was explored. The investigators found that brain interstitial fluid levels of Aβ in transgenic mice fluctuated over a 24-hour period with lower levels during sleep and higher levels during wakefulness. Moreover, sleep-depriving the mice caused an increase in plaque load, but this effect could be abolished by treating the mice with Almorexant, a receptor antagonist of orexin—a molecule regulating the sleep-wake cycle. Finally, the researchers also looked at human CSF Aβ levels and found similar alterations over the day. This study provides important new evidence that Aβ formation and plaque deposition can be controlled by affecting the sleep pattern. Also, the work adds a new perspective to the use of CSF Aβ as a diagnostic marker, as the reference values may have to be adjusted to the sampling timepoints.

View all comments by Martin Ingelsson
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad